Hepatitis C virus/human T lymphotropic virus 1/2 coinfection:Regional burden and virological outcomes in people who inject drugs

• 作者: Elena Roger Erika Castro
• 来源期刊: 世界病毒学杂志
• 学科: 医学
• 关键词: HEPATITIS C VIRUS HUMAN T lymphotropic VIRUS HEPATITIS C virus/human T lymphotropic virus-1/2 CO-INFECTION People who inject DRUGS HUMAN T lymphotropic virus-1/2 screening among people who inject DRUGS CO-INFECTION treatment
• 年，卷（期）: sjbdxzz,（2）
• 页码范围: 68-72
• 页数: 5页
• 分类号: R

摘要

This review analyses current data concerning co-infection with hepatitis C virus(HCV)and human T lymphotropic virus(HTLV)-1/2 in people who inject drugs(PWID),with a particular focus on disease burden and global implications for virological outcome.In addition,the available treatment options for HTLV-1/2 are summarized and the on-going and likely future research challenges are discussed.The data in this review was obtained from 34 articles on HCV/HTLV-1/2 co-infection in PWID retrieved from the PubMed literature database and published between 1997 and 2015.Despite unavailable estimates of the burden of HCV/HTLV-1/2 co-infection in general,the epidemiologic constellation of HTLV-1/2 shows high incidence in PWID with history of migration,incarceration,and other blood-borne infectious diseases such as HCV or human immunodeficiency virus.The most recent research data strongly suggest that HTLV-1 co-infection can influence HCV viral load,HCV sustained virological response toα-interferon treatment,and HCV-related liver disease progression.In short,outcome of HCV infection is worse in the context of HTLV-1 co-infection,yet more studies are needed to gain accurate estimations of the burden of HCV/HTLV-1/2 co-infections.Moreover,in the current era of new direct-acting antiviral treatments for HCV and proven HTLV-1/2 treatment options,prospective clinical and treatment studies should be carried out,with particular focus on the PWID patient population,with the aim of improving virological outcomes.